The present invention is concerned with 1,2,4,5-tetrahydro-benzo[d]azepin derivatives as well as with their pharmaceutically acceptable salts in their racemic and optically active form, which compounds are antagonists at metabotropic glutamate receptors and therefore useful for the treatment of diseases related to these receptors.
4-(N,N-Dialkylthiocarbamoylthio)-5-nitropyrimidines as new potential nitric oxide donors
作者:O. B. Ryabova、E. Yu. Khmel’nitskaya、V. A. Makarov、L. M. Alekseeva、N. B. Grigor’ev、V. G. Granik
DOI:10.1007/s11172-006-0203-5
日期:2005.12
On heating at pH 6.86, 4-(N,N-dialkylthiocarbamoylthio)-5-nitropyrimidines are transformed into dithiolopyrimidines, which are either oxidized to bis(4-dialkylthiocarbamoylpyrimidin-5-yl) disulfides or converted into 4,6-diamino-5-nitropyrimidine derivatives with carbon disulfide elimination. The direction of the reaction is determined by the nature of a substituent in position 2 of pyrimidine and the bulk of the thiocarbamate substituent. Mechanistic schemes for these processes were proposed.
Pyrrolo[2, 3-d]pyrimidines and pyrrolo[3, 2-d]pyrimidines were synthesized in high yields by the palladiumcatalyzed reaction of 4-acetylamino-5-bromopyrimidines and 5-acetylamino-4-iodopyrimidines with (Z)-1-ethoxy-2-(tributylstannyl)ethene followed by cyclization under acidic conditions.
mGluR antagonists and a method for their synthesis
申请人:Hoffmann-La Roche Inc.
公开号:US06369222B1
公开(公告)日:2002-04-09
The invention relates to nitro- and cyano-1,2,4,5-tetrahydro-heterocycloazepinyl pyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to medicaments containing such compounds and a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control or prevention of acute and/or chronic neurological disorders.
Novel mGluR antagonists and a method for their synthesis
申请人:——
公开号:US20020045635A1
公开(公告)日:2002-04-18
The invention relates to nitro- and cyano-1,2,4,5-tetrahydro-heterocycloazepinyl pyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to medicaments containing such compounds and a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control or prevention of acute and/or chronic neurological disorders.